Companion diagnostic for htra1 rna antagonists
AssigneeHoffmann-La Roche Inc.
InventorsRubén Alvarez Sánchez, Roberto Iacone, Peter Jakob, Jean-Luc Mary, Heidi Rye Hudlebusch, Thomas Peter John Dunkley, Corinne Stucki, Ulrich Friedrich Oskar Luhmann, Carolin Rakebrandt
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of HTRA1 mRNA antagonists in the treatment of eye disorders, such as macular degeneration, and the use of an HTRA1 levels in the aqueous and vitreous humor as a diagnostic biomarker for the suitability of treatment of a subject with an HTRA1 mRNA antagonist.
Claims20
A method for determining the suitability of treatment of a subject for administration with an HTRA1 mRNA antagonist, said method comprising the steps of:
- i) determining the level of HTRA1 in a sample of aqueous or vitreous humor obtained from the subject
- ii) comparing the level of HTRA1 obtained from step i) with one or more reference samples or reference values;
- to determine whether the subject is likely to be, or is suitable for, treatment of with the HTRA1 mRNA antagonist,
- wherein the subject is suffering from or is at risk of developing an ocular disorder, such as macular degeneration.
-23. (canceled)
Dependencies are inferred from the claim text.